Clinical TrialsThe initiation of the Phase 3 SERENITY At-Home study for Igalmi is seen as a positive development, potentially driving increased revenue.
Regulatory ProgressBTAI shares are trading +150% after announcing that the FDA has concluded the site inspection for one of the sites in the TRANQUILITY II phase 3 trial, with voluntary action indicated.
Strategic DevelopmentsBTAI is no longer required to run the TRANQUILITY At-Home study, which is considered a net incremental positive.